While many research efforts have illustrated the capability of these agents to suppress neuroinflammation, most have not advanced to the stage of clinical trials
Disclosures: Chanda Ho: Nothing to Disclose, Janet Chu: Gilead Sciences, Inc.: Grant/Research Support, Aly Cortella: Nothing to Disclose, Alison Canchola: Nothing to Disclose, Pushkar Inamdar: Nothing to Disclose, Pragati Kenkare: Nothing to Disclose, Jane Vu: Nothing to Disclose, Sixiang Nie: Nothing to Disclose, Ma Somsouk: Nothing to Disclose, Michele Tana: Nothing to Disclose, Caroline Thompson: Nothing to Disclose, Scarlett Gomez: Nothing to Disclose, Hashem El-Serag: Nothing to Disclose, Miok Kim: Nothing to Disclose, Mark Segal: Nothing to Disclose, Yihe Daida: Vir Biotechnology: Grant/Research Support, Sanofi: Grant/Research Support, GSK: Grant/Research Support, Su-Ying Liang: Nothing to Disclose, Mindy Hebert-Derouen: Nothing to Disclose, Salma Shariff-Marco: Nothing to Disclose 934 SAFETY AND EFFICACY OF CONTRACEPTIVE AGENTS AFTER LIVER TRANSPLANTATION Grace Zhang 1 Cynthia Fenton 2 Dominika Seidman 3 Elle Oberweis-Manion 3 Monika Sarkar 1 , 1 University of California, San Francisco, 2 University of California San Franscisco, 3 University of California San Francisco Background: The number of reproductive-aged liver transplant (LT) recipients is rising, and fertility is rapidly restored in the post-operative setting
doi: 10.1016/j.ijbiomac.2025.148939 57 LiF.MaoZ.DuY.CuiY.YangS.HuangK.et al
Although the mechanism the pill, now owned by Eli Lilly, is based on is similar to that of the ruxolitinib cream, Lee said the pill is more effective at treating cells found deeper in the skin, such as hair cells
